Skip to main content

Table 4 Logistic multivariable analysis for Lymphocyte-Monocyte Ratio

From: Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation

 

aOR

95% CI

P

Gender

 Male

Reference

  

 Female

0.88

0.78–1.00

0.05

Smoker

 Never/Former

Reference

  

 Current

1.04

0.92–1.16

0.56

Age

  < 65

Reference

  

 65 or older

1.03

0.93–1.14

0.61

KPS

  < 90

Reference

  

 90–100

0.94

0.84–1.04

0.23

 Not available

0.97

0.59–1.59

0.9

Race

 White

Reference

  

 Other

0.85

0.74–0.97

0.02

Comorbidity

 0

Reference

  

 1–3

0.93

0.82–1.06

0.3

  > 3

0.91

0.78–1.06

0.21

Site

 Oropharynx

Reference

  

 Larynx

0.87

0.75–1.00

0.05

 Other

1

0.88–1.14

1

T staging

 1–2

Reference

  

 3–4

1.15

1.04–1.27

0.005

N staging

 0–1

Reference

  

 2–3

1.04

0.93–1.17

0.47

HPV

 Negative

Reference

  

 Positive

0.82

0.72–0.94

0.005

Not available

0.93

0.82–1.06

0.26

 Chemo

 Cisplatin

Reference

  

 Other

1.12

0.98–1.27

0.1

  1. aOR adjusted odds ratio, 95% CI 95% confidence interval, KPS Karnofsky performance status, HPV human papillomavirus